


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199070</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1742-4658</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The FEBS journal</Title>
                <ISOAbbreviation>FEBS J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Structural insights into Entamoeba histolytica arginase and structure-based identification of novel non-amino acid based inhibitors as potential antiamoebic molecules.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.14960</ELocationID>
            <Abstract>
                <AbstractText>Arginase, the binuclear metalloenzyme, is a potential target for therapeutic intervention in protozoan infections. Entamoeba histolytica infection causes amebiasis which is the second most common cause of protozoan-related human deaths after malaria. Here, we report the crystal structure of E. histolytica arginase (EhArg) in complex with two known inhibitors N<sup>ω</sup> -hydroxy-L-arginine (L-NOHA) and L-norvaline, and its product L-ornithine at 1.7 Å, 2.0 Å and 2.4 Å respectively. Structural and comparative analysis of EhArg-inhibitor complexes with human arginase (HArg) revealed that despite of only 33% sequence identity, the structural determinants of inhibitor recognition and binding are highly conserved in arginases with variation in oligomerization motifs. Knowledge regarding the spatial organization of residues making molecular contacts with inhibitory compounds enabled in the identification of four novel non-amino acid inhibitors viz. irinotecan, argatroban, cortisone acetate and sorafenib. In vitro testing of the in silico identified inhibitors using purified enzyme proved that irinotecan, argatroban, cortisone acetate and sorafenib inhibit EhArg with IC<sub>50</sub> value (mM) of 1.99, 2.40, 0.91 and 2.75 respectively as compared to the known inhibitors L-NOHA and L-norvaline with IC<sub>50</sub> value (mM) of 1.57 and 17.9 respectively. Identification of structure-based non-amino acid inhibitory molecules against arginase will be constructive in design and discovery of novel chemical modulators for treating amebiasis by directed therapeutics. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Malik</LastName>
                    <ForeName>Anjali</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, 247667, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dalal</LastName>
                    <ForeName>Vikram</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, 247667, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ankri</LastName>
                    <ForeName>Serge</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Microbiology, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomar</LastName>
                    <ForeName>Shailly</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, 247667, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>FEBS J</MedlineTA>
            <NlmUniqueID>101229646</NlmUniqueID>
            <ISSNLinking>1742-464X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">
Entamoeba histolytica
</Keyword>
            <Keyword MajorTopicYN="N">L-NOHA</Keyword>
            <Keyword MajorTopicYN="N">L-norvaline</Keyword>
            <Keyword MajorTopicYN="N">L-ornithine</Keyword>
            <Keyword MajorTopicYN="N">arginase</Keyword>
            <Keyword MajorTopicYN="N">crystal structure</Keyword>
            <Keyword MajorTopicYN="N">structure-based drug designing</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199070</ArticleId>
            <ArticleId IdType="doi">10.1111/febs.14960</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

